regulatory T cells

[Nature Reviews Rheumatology] Restoration of Treg cell fitness and/or expansion of their numbers using low-dose natural IL-2, the main cytokine driving Treg cell survival and function, has demonstrated clinical efficacy in early clinical trials.

[Molecular Therapy-Methods & Clinical Development] In mouse models, AAV-CAR Tregs mediated continued transgene expression from an immunogenic capsid, despite antibody responses, produced immunosuppressive cytokines, and decreased tissue inflammation.

[Diabetologia] Researchers profiled CD4+ regulatory T cells in a small but well-characterized cohort of extreme slow progressors with a median age 43, followed up for 18–32 years.

[Nature Communications] The authors showed in mouse melanoma and breast cancer models that regulatory T cells expressing the β8 chain of αvβ8 integrin are the main cell type in the tumors that activated TGFβ, produced by the cancer cells and stored in the tumor micro-environment.

[Nature Communications] Scientists showed in mouse melanoma and breast cancer models that regulatory T cells expressing the β8 chain of αvβ8 integrin were the main cell type in the tumors that activated TGFβ, produced by the cancer cells and stored in the tumor microenvironment.

[Cell Death & Disease] Scientists focused on the BCL-2 specific inhibitor venetoclax and its effects following short-term and long-term BCL-2 blockade on T cell subsets.